Abstract
This article shortly summarizes results from a clinical trial in idiopathic pain syndromes. In order to evaluate the clinical effect of antidepressants in patients with idiopathic pain syndromes a noradrenaline reuptake inhibitor (maprotiline) and a serotonin reuptake inhibitor (clomipramine) were given to 70 patients for six weeks in a randomized double-blind multicentre trial. Eighteen patients were excluded during the study. In addition to pain, 16 depressive symptoms were observed. Clomipramine-treated patients showed an overall improvement of 63%, and maprotiline-treated patients reported a 36% improvement (p<0.05). Side effects were generally mild. Eight patients in the clomipramine group and one in the maprotiline group were excluded due to side effects. The 3H-imipramine receptor binding to platelets in chronic idiopathic pain patients was measured. The Bmax values were decreased by 11% prior to treatment. Maprotiline treatment tended to increase the values towards those of healthy controls, while...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
